Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy
European Journal of Nuclear Medicine and Molecular Imaging · 2025-05 · 52 (6) · 2015-2022
DOI: 10.1007/s00259-025-07076-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 13.01.2025. Verfasst von Mike Wenzel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt Am Main, Frankfurt, Germany. Mike.Wenzel@unimedizin-ffm.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Radioisotopes, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johann Wolfgang Goethe-Universität, Frankfurt am Main.
Abstract (Originalsprache)
Purpose
Lutetium-177 Prostate-specific membrane antigen (Lu-PSMA) radioligand therapy is EMA-approved for metastatic castration resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition (ARPI) and taxan-based chemotherapy. However, its effect in taxan-naïve patients is under current investigation.
Methods
We relied on the FRAMCAP database to elaborate Lu-PSMA therapy outcomes of progression-free (PFS) and overall (OS) in taxan-naïve mCRPC patients after previous ARPI treatment. Comparison was made against current standard of care with ARPI or docetaxel, irrespective of the previous used staging modality.
Results
Of 269 patients, 11% received Lu-PSMA in first/second-line mCRPC vs. 57% ARPI vs. 33% docetaxel. Mostly no significant baseline differences between Lu-PSMA and ARPI patients were observed, while Lu-PSMA patients were significantly older, received less systematic treatments and ECOG1-2 proportions were higher, relative to docetaxel patients. In PFS (13.3 vs. 8.2 months, hazard ratio [HR]: 0.70, p = 0.16) and OS analyses (68.9 vs. 39.1 months, HR: 0.64, p = 0.2), Lu-PSMA was numerically more favorable than ARPI. In additional multivariable Cox regression models, Lu-PSMA was significant better regarding PFS and OS, relative to ARPI (both p < 0.05). Compared to docetaxel, also significant better PFS (13.3 vs. 8.1 months, HR: 0.46) and OS (68.9 vs. 27.3 months, HR: 0.34, both p < 0.01) was observed for Lu-PSMA treatment. The OS advantage was also observed after multivariable adjustment ( p < 0.01).
Conclusion
This retrospective single-center study including a substantial proportion of patients with treatment preference for Lu-PSMA suggests that Lu-PSMA therapy provides significantly more favorable PFS and OS outcomes in taxan-naïve mCRPC patients after previous ARPI treatment, relative to ARPI or docetaxel treatment and may be considered as an early mCRPC treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt Am Main, Frankfurt, Germany. Mike.Wenzel@unimedizin-ffm.de.
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt Am Main, Frankfurt, Germany.
- Department of Nuclear Medicine, University Hospital Frankfurt, Goethe University Frankfurt Am Main, Frankfurt, Germany.
- Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
ORCID-Profile: Mike Wenzel
Förderung
- Johann Wolfgang Goethe-Universität, Frankfurt am Main
Zitieren
APA
Wenzel, M., Hoeh, B., Siech, C., Koll, F., Humke, C., Groener, D., Steuber, T., Graefen, M., Maurer, T., Banek, S., Chun, F. K. H., & Mandel, P. (2025). Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy. European Journal of Nuclear Medicine and Molecular Imaging, 52(6), 2015-2022. https://doi.org/10.1007/s00259-025-07076-7
Vancouver
Wenzel M, Hoeh B, Siech C, Koll F, Humke C, Groener D, et al. Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(6):2015-2022. doi:10.1007/s00259-025-07076-7
BibTeX
@article{Wenzel2025,
author = {Wenzel, Mike and Hoeh, Benedikt and Siech, Carolin and Koll, Florestan and Humke, Clara and Groener, Daniel and Steuber, Thomas and Graefen, Markus and Maurer, Tobias and Banek, Severine and Chun, Felix K H and Mandel, Philipp},
title = {Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {52},
number = {6},
pages = {2015--2022},
doi = {10.1007/s00259-025-07076-7}
}
EUVIMED